亚裔美国人慢性乙型肝炎管理专家共识
该专家共识针对亚裔美国人HBV感染管理提出推荐,基于亚洲国家数据及亚裔美国人研究,在HBeAg阳性/阴性CHB治疗、HCC监测及孕妇管理上与其他指南不同。推荐包括抗病毒治疗指征、终生监测和影像学复查频率,并按证据等级分类。
要点
- HBeAg阳性或阴性、HBV DNA>2000 IU/mL且ALT高于正常者考虑抗病毒治疗。
- HBeAg阴性、HBV DNA>2000 IU/mL、ALT正常但白蛋白<3.5 g/dL或血小板<130 000 mm3等者应治疗。
- HBsAg阳性高危者每6个月AFP和腹部超声监测HCC,接受HCC治疗者每3个月增强CT或MRI复查。
核心结论
- 基于文献回顾和亚裔美国医生专家小组意见的推荐可指导医生并改善患者结局。
研究设计与样本
- 专家共识,基于亚洲国家HBV医学报告及亚裔美国人HBsAg阳性研究数据制定。
主要发现
- 亚裔美国人HBsAg携带率为2%至16%,近似其原籍国水平。
- HBV是全世界HBsAg阳性亚洲人肝硬化、HCC和肝相关死亡的最重要原因。
关键数值与推荐
- HBeAg阳性或阴性、HBV DNA>2000 IU/mL(>10^4 copies/mL)且ALT高于正常者为抗病毒治疗候选者。
- HBeAg阴性、HBV DNA>2000 IU/mL、ALT正常但血清白蛋白<3.5 g/dL或血小板计数<130 000 mm3、有基底核心启动子(BCP)突变或一级亲属有HCC者应给予治疗。
- 肝硬化且HBV DNA可检测者必须接受终生抗病毒治疗。
- 治疗指征包括高病毒血症孕妇、合并感染者及需免疫抑制治疗者。
- HBsAg阳性高危者需每6个月进行AFP检测和腹部超声终生监测HCC。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin. Similarly, HBV is the most important cause of cirrhosis, hepatocellular carcinoma (HCC) and liver related deaths in HBsAg positive Asians worldwide. AIM: To generate recommendations for the management of Asian Americans infected with HBV. METHODS: These guidelines are based on relevant data derived from medical reports on HBV from Asian countries as well as from studies in the HBsAg positive Asian Americans. The guidelines herein differ from other recommendations in the treatment of both HBeAg positive and negative chronic hepatitis B (CHB), in the approach to HCC surveillance, and in the management of HBV in pregnant women. RESULTS: Asian American patients, HBeAg positive or negative, with HBV DNA levels >2000 IU/mL (>104 copies/mL) and ALT values above normal are candidates for anti-viral therapy. HBeAg negative patients with HBV DNA >2000 IU/mL and normal ALT levels but who have either serum albumin <3.5 g/dL or platelet count <130 000 mm3 , basal core promoter (BCP) mutations, or who have first-degree relatives with HCC should be offered treatment. Patients with cirrhosis and detectable HBV DNA must receive life-long anti-viral therapy. Indications for treatment include pregnant women with high viraemia, coinfected patients, and those requiring immunosuppressive therapy. In HBsAg positive patients with risk factors, life-long surveillance for HCC with alpha-fetoprotein (AFP) testing and abdominal ultrasound examination at 6-month intervals is required. In CHB patients receiving HCC treatments, repeat imaging with contrast CT scan or MRI at 3-month intervals is strongly recommended. These guidelines have been assigned to a Class (reflecting benefit vs. risk) and a Level (assessing strength or certainty) of evidence. CONCLUSIONS: Application of the recommendations made based on a review of the relevant literature and the opinion of a panel of Asian American physicians with expertise in HBV treatment will inform physicians and improve patient outcomes.
引用
- Tong MJ, Pan CQ, Han SB, et al. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther. 2018. PMID: 29479728. doi:10.1111/apt.14577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。